Welcome to the Takeda Oncology Newsroom. This section is dedicated to providing the most up-to-date information about our company, our people and our science.
If you are a reporter, please contact:
Phone: 617-444-1400
Email: TakedaOncologyNews@takeda.com
For other Takeda news releases, please visit the Takeda.com Newsroom.
Takeda China announces ADCETRIS® (brentuximab vedotin) is approved for the treatment of adult patients with CD30-positive Lymphomas
European Commission Approves ADCETRIS® (brentuximab vedotin) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma
Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib (TAK-788) for the Treatment of NSCLC Patients with EGFR Exon 20 Insertion Mutations
